3 ASX shares that look EXTREMELY overvalued

CSL Limited (ASX:CSL), Cochlear Limited (ASX:COH) and Bellamy's Australia Ltd (ASX:BAL) look extremely overvalued compared to the S&P/ASX 200 (Index:^AXJO)(ASX:XJO).

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

When most people scan for new shares to buy, chances are, they include some valuation metric like the price-earnings ratio or P/E.

As we know, the P/E puts a company's share price, P, in a ratio with earnings, E. We are taught a lower P/E is preferred to a higher P/E.

A herd mentality

The general consensus among investors is the lower P/E is better for us because we get more earnings (or profits) for every dollar we invest.

However, what many investors fail to consider is the quality of those earnings. We often say 'we'd pay up for growth', meaning we'd consider owning a high P/E share. However, in reality, this is uncomfortable because it goes against what we are taught (i.e. the herd).

Overvalued or overlooked?

For some investors, overlooking a high P/E is — arguably — the most appropriate course of action. For example, a retiree shouldn't own an entire portfolio of high P/E shares with no dividends (or so we're taught).

For other investors, challenging conventional wisdom by buying only 'overvalued' shares has proven to be a terrific investment strategy.

The Motley Fool's Co-Founder, David Gardner, uses such an approach. His 'Rule Breakers' investment strategy has delivered some spectacular returns (as well as some not so spectacular returns) by focusing on shares which challenge conventional valuation techniques.

He summed up the process perfectly in the following quote, taken from this article written in 2006:

"If a company is growing its earnings and, as a result, has an increasing valuation, there will be someone somewhere arguing that the company is overvalued. This is valuable, because it keeps people out of a stock; later on, as the company proves out its position as a profitable, even dominant, leader, then the sceptics finally buy — which is what can give you serious appreciation as an early investor in these growth stocks!"

That's one rule David uses to find great companies early in their lifecycle.

Home Grown Rule Breakers

Using the same strategy on the ASX, many Australian investors would have overlooked CSL Limited (ASX: CSL) in its early years because it appeared overvalued. CSL shares are up 2,418% in 15 years. The same can be said of Cochlear Limited (ASX: COH), which is up 1,000%.

Both sets of returns exclude dividends paid.

Is this ASX share overlooked?

Perhaps it's time to ask ourselves: Which shares have recently been labelled 'overvalued'?

Bellamy's Australia Ltd (ASX: BAL) springs to mind. It is a small company operating in a very big market. Its shares are up 646% in two years. Bellamy's shares trade at more than three times the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) average P/E ratio of 16x.

Foolish takeaway

Don't for a second believe there isn't a method to the madness of buying 'overvalued' shares.

Overvalued shares can be expensive for many good reasons. For example, companies that can forge a competitive advantage and earn excess returns from their investments will soon make up the valuation gap on their cheaper lower 'quality' peers.

Not every investment we make will be a winner, either. But it's important we remind ourselves that we cannot lose more than 100% of our investment — yet we can make much more — and as David wrote: "You can't score if you don't shoot".

Motley Fool Contributor Owen Raszkiewicz owns shares of Cochlear Limited and CSL Limited and has a financial interest in Bellamy's Australia. You can follow Owen on Twitter @ASXinvest. The Motley Fool Australia owns shares of Bellamy's Australia. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »